Biomarker identification and pathway analysis by serum metabolomics of childhood acute lymphoblastic leukemia

Clinica Chimica Acta

Volumn 436, Issue , 2014, Pages 207-216

  Bai, Yunnuo ^a   Zhang, Haitao ^a   Sun, Xiaohan ^a   Sun, Changhao ^a   Ren, Lihong ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Acute lymphoblastic leukemia; Biomarkers; Metabolomics; Pathway analysis; UPLC Q TOF

Indexed keywords

ARACHIDONIC ACID; BIOLOGICAL MARKER; GLYCEROPHOSPHOLIPID; GLYCOSYLPHOSPHATIDYLINOSITOL; LINOLEIC ACID; TUMOR MARKERS, BIOLOGICAL;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BONE MARROW BIOPSY; CHEMICAL COMPOSITION; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; DISEASE COURSE; HUMAN; LIPID METABOLISM; LIQUID CHROMATOGRAPHY; METABOLOMICS; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUADRUPOLE MASS SPECTROMETRY; SCORING SYSTEM; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; BLOOD; CASE-CONTROL STUDIES; CHILD; DISCRIMINANT ANALYSIS; HUMANS; METABOLISM; METHODS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRINCIPAL COMPONENT ANALYSIS;

CASE-CONTROL STUDIES; CHILD; DISCRIMINANT ANALYSIS; HUMANS; METABOLOMICS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRINCIPAL COMPONENT ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84902579080     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.05.022     Document Type: Article

References (38)

1. Onciu M. Acute lymphoblastic leukemia. Hematol Oncol Clin North Am 2009, 23:655-674.
2. Gurney J.G., Severson R.K., Davis S., Robison L.L. Incidence of cancer in children in the United States. Sex-, race-, and 1-year age-specific rates by histologic type. Cancer 1995, 75:2186-2195.
3. Pui C.H. Acute lymphoblastic leukemia in children. Curr Opin Oncol 2000, 12:3-12.
4. Pui C.H., Relling M.V., Campana D., Evans W.E. Childhood acute lymphoblastic leukemia. Rev Clin Exp Hematol 2002, 6:161-180. [discussion 200-162].
5. Diamanti P., Cox C.V., Moppett J.P., Blair A. Parthenolide eliminates leukemia-initiating cell populations and improves survival in xenografts of childhood acute lymphoblastic leukemia. Blood 2013, 121:1384-1393.
6. Nicholson J.K., Lindon J.C., Holmes E. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999, 29:1181-1189.
7. Spratlin J.L., Serkova N.J., Eckhardt S.G. Clinical applications of metabolomics in oncology: a review. Clin Cancer Res 2009, 15:431-440.
8. Glunde K., Jie C., Bhujwalla Z.M. Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res 2004, 64:4270-4276.
9. Zira A.N., Theocharis S.E., Mitropoulos D., Migdalis V., Mikros E. (1)H NMR metabonomic analysis in renal cell carcinoma: a possible diagnostic tool. J Proteome Res 2010, 9:4038-4044.
10. Ganti S., Weiss R.H. Urine metabolomics for kidney cancer detection and biomarker discovery. Urol Oncol 2011, 29:551-557.
11. Yin P., Wan D., Zhao C., et al. A metabonomic study of hepatitis B-induced liver cirrhosis and hepatocellular carcinoma by using RP-LC and HILIC coupled with mass spectrometry. Mol Biosyst 2009, 5:868-876.
12. Keun H.C., Sidhu J., Pchejetski D., et al. Serum molecular signatures of weight change during early breast cancer chemotherapy. Clin Cancer Res 2009, 15:6716-6723.
13. Gu H., Pan Z., Xi B., Asiago V., Musselman B., Raftery D. Principal component directed partial least squares analysis for combining nuclear magnetic resonance and mass spectrometry data in metabolomics: application to the detection of breast cancer. Anal Chim Acta 2011, 686:57-63.
14. Chen Y., Zhang R., Song Y., et al. RRLC-MS/MS-based metabonomics combined with in-depth analysis of metabolic correlation network: finding potential biomarkers for breast cancer. Analyst 2009, 134:2003-2011.
15. Asiago V.M., Alvarado L.Z., Shanaiah N., et al. Early detection of recurrent breast cancer using metabolite profiling. Cancer Res 2010, 70:8309-8318.
16. Ma Y., Liu W., Peng J., et al. A pilot study of gas chromatograph/mass spectrometry-based serum metabolic profiling of colorectal cancer after operation. Mol Biol Rep 2010, 37:1403-1411.
17. Ma Y., Zhang P., Wang F., Liu W., Yang J., Qin H. An integrated proteomics and metabolomics approach for defining oncofetal biomarkers in the colorectal cancer. Ann Surg 2012, 255:720-730.
18. Lokhov P.G., Dashtiev M.I., Bondartsov L.V., Lisitsa A.V., Moshkovskii S.A., Archakov A.I. Metabolic fingerprinting of blood plasma for patients with prostate cancer. Biomed Khim 2009, 55:247-254.
19. Trock B.J. Application of metabolomics to prostate cancer. Urol Oncol 2011, 29:572-581.
20. Zhou J., Xu B., Huang J., et al. 1H NMR-based metabonomic and pattern recognition analysis for detection of oral squamous cell carcinoma. Clin Chim Acta 2009, 401:8-13.
21. Bathe O.F., Shaykhutdinov R., Kopciuk K., et al. Feasibility of identifying pancreatic cancer based on serum metabolomics. Cancer Epidemiol Biomarkers Prev 2011, 20:140-147.
22. Zhang J., Liu L., Wei S., et al. Metabolomics study of esophageal adenocarcinoma. J Thorac Cardiovasc Surg 2011, 141:469-475. [475 e461-464].
23. Zhang Z., Qiu Y., Hua Y., et al. Serum and urinary metabonomic study of human osteosarcoma. J Proteome Res 2010, 9:4861-4868.
24. Rocha C.M., Carrola J., Barros A.S., et al. Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of blood plasma. J Proteome Res 2011, 10:4314-4324.
25. Tili E., Michaille J.J., Luo Z., et al. The down-regulation of miR-125b in chronic lymphocytic leukemias leads to metabolic adaptation of cells to a transformed state. Blood 2012, 120:2631-2638.
26. Zeidler L., Zimmermann M., Moricke A., et al. Low platelet counts after induction therapy for childhood acute lymphoblastic leukemia are strongly associated with poor early response to treatment as measured by minimal residual disease and are prognostic for treatment outcome. Haematologica 2012, 97:402-409.
27. Frolova O., Samudio I., Benito J.M., et al. Regulation of HIF-1alpha signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment. Cancer Biol Ther 2012, 13:858-870.
28. Zhang A., Sun H., Yan G., Han Y., Ye Y., Wang X. Urinary metabolic profiling identifies a key role for glycocholic acid in human liver cancer by ultra-performance liquid-chromatography coupled with high-definition mass spectrometry. Clin Chim Acta 2013, 418:86-90.
29. Qiu Y., Zhou B., Su M., et al. Mass spectrometry-based quantitative metabolomics revealed a distinct lipid profile in breast cancer patients. Int J Mol Sci 2013, 14:8047-8061.
30. Xu J., Chen Y., Zhang R., et al. Global and targeted metabolomics of esophageal squamous cell carcinoma discovers potential diagnostic and therapeutic biomarkers. Mol Cell Proteomics 2013, 12:1306-1318.
31. Zhang T., Wu X., Yin M., et al. Discrimination between malignant and benign ovarian tumors by plasma metabolomic profiling using ultra performance liquid chromatography/mass spectrometry. Clin Chim Acta 2012, 413:861-868.
32. Ressom H.W., Xiao J.F., Tuli L., et al. Utilization of metabolomics to identify serum biomarkers for hepatocellular carcinoma in patients with liver cirrhosis. Anal Chim Acta 2012, 743:90-100.
33. Wang Y., Gao D., Chen Z., et al. Acridone derivative 8a induces oxidative stress-mediated apoptosis in CCRF-CEM leukemia cells: application of metabolomics in mechanistic studies of antitumor agents. PLoS One 2013, 8:e63572.
34. Kim I.C., Lee J.H., Bang G., et al. Lipid profiles for HER2-positive breast cancer. Anticancer Res 2013, 33:2467-2472.
35. Ishikawa S., Tateya I., Hayasaka T., et al. Increased expression of phosphatidylcholine (16:0/18:1) and (16:0/18:2) in thyroid papillary cancer. PLoS One 2012, 7:e48873.
36. Ridgway N.D. The role of phosphatidylcholine and choline metabolites to cell proliferation and survival. Crit Rev Biochem Mol Biol 2013, 48:20-38.
37. Cadenas C., Vosbeck S., Hein E.M., et al. Glycerophospholipid profile in oncogene-induced senescence. Biochim Biophys Acta 1821, 2012:1256-1268.
38. Dolce V., Cappello A.R., Lappano R., Maggiolini M. Glycerophospholipid synthesis as a novel drug target against cancer. Curr Mol Pharmacol 2011, 4:167-175.